MétaCan
Menu
Back to cohort

S107 Can plasma Cell-free DNA methylation predict response to mepolizumab in asthmatic individuals?

2025· article· W4416104296 on OpenAlexaff
Poojitha Rajasekar, Jamie Patel, Julie L. MacIsaac, Michael S. Kobor, YL Pang, Ian Sayers, D Shaw, RL Clifford

Bibliographic record

Venuenot available
Typearticle
Language
FieldSocial Sciences
TopicDelphi Technique in Research
Canadian institutionsBC Children's HospitalUniversity of British Columbia
Fundersnot available
KeywordsMepolizumabdNaMDNA methylationAsthmaLocus (genetics)BiomarkerGenotypeEpigenetics

Abstract

fetched live from OpenAlex

Rationale Monoclonal antibody therapies are used to treat severe asthma. Mepolizumab was the first anti-cytokine therapy introduced, and it targets IL-5. It effectively reduces steroid use and exacerbations in some severe asthma patients but approximately one third of treated patients do not havea clinically significant reduction inexacerbations and oral steroid use at 12 months post-treatment. An early biomarker that was predictive of clinical response at one year would reduce patient burden, improve management and have associated cost saving.Cell free DNA (cfDNA) are DNA fragments released into bodily fluids carrying cell/tissue-specific epigenetic patterns called DNA methylation (DNAm) that reflect their origin. cfDNAm offers tissue specific specificity to systemic samples. We have shown DNAm changes in the nasal epithelium after Mepolizumab treatment [PMID: 38386780] and distinct plasma cfDNAm profiles between asthmatic and non-asthmatic individuals. Objective To identify cfDNAm signatures that differ between Mepolizumab responders (R) and non-responders (NR) pre-treatment and after 3 months of treatment. Methods cfDNA was extracted (Maxwell® RSC ccfDNA Plasma Kit) from 1 ml blood plasma of 14 asthmatic individuals (9 R; 5 NR identified at 12 months) at baseline and 3 months of Mepolizumab treatment [part of Investigating Poor Response to Monoclonal therapy in Asthma study]. DNAm was profiled using the Illumina EPIC Array. Linear regression assessed differential cfDNAm between R and NR. Results A single DNAm locus was identified with a significant (Benjamini-Hochberg p<0.05) decrease (~8%) in methylation between baseline and 3 months among Mepolizumab responders, while non-responders exhibited an increase (~4%). A 213bp region around this locus with 4 adjacent loci was identified to be evaluated as potential early response biomarker. Linear regression analysis within each time point identified DNAm changes (pre-treatment = 1838; 3 months post treatment =1283, nominal p<0.001) between R and NR. The two most significant and consistent loci have been selected to evaluate as potential biomarkers. Conclusion Plasma cfDNAm signatures have been identified for further investigation as early predictors of patient response to Mepolizumab. Evaluation of their potential as biomarkers using pyrosequencing in a blinded blood plasma sample cohort of Mepolizumab treated severe asthmatic individuals is ongoing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.401
Teacher spread0.353 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same topicDelphi Technique in ResearchFrench-language works237,207